A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 67
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IBC
Long Form : invasive breast carcinoma
No. Year Title Co-occurring Abbreviation
2022 CD8+ TILS Expression in Invasive Breast Carcinoma (No Special Type). IBC-NST, MHC class I, TILs
2022 Clinicopathologic and Molecular Characteristics of and Diagnostic Dilemmas in Invasive Breast Carcinoma with Choriocarcinomatous Pattern apropos a New Case: A Literature Review with New Findings. beta-hCG, IBC-CP, MC-B, NGS
2022 S-phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma. SPF
2021 Human Papillomavirus (HPV) Detection by Chromogenic In Situ Hybridization (CISH) and p16 Immunohistochemistry (IHC) in Breast Intraductal Papilloma and Breast Carcinoma. CISH, DCIS, HPV, IHC
2021 Intratumor Heterogeneity of Synchronous In Situ and Invasive Breast Carcinoma Revealed Using Multi-region Exome Sequencing. DCIS, ITH
2021 Molecular alterations differentiate microinvasive carcinoma from ductal carcinoma in situ and invasive breast carcinoma: retrospective analysis of a large single-center series. DCIS, ER, HER2, MIC, PR
2021 New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes. ---
2021 Underestimation of invasive breast carcinoma in patients with initial diagnosis of ductal carcinoma in situ: Size matters. BCS, DCIS, SLNB
2021 Underestimation of invasive breast carcinoma in patients with initial diagnosis of ductal carcinoma in situ: Size matters. BCS, DCIS, SLNB
10  2020 An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications. Drp1, NSCLC
11  2020 Clinicopathological Characteristics of PIK3CA Mutation and Amplification in Korean Patients with Breast Cancers. ---
12  2020 Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma. GATA3
13  2020 Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors. DCIS, MRI
14  2020 Mixed Invasive Apocrine Papillary/Micropapillary Carcinoma of the Breast: Another Brick in the Triple-Negative Wall. CNB, ER/PR, IPC
15  2019 Comparative analysis of margin status in breast conservation surgery and its correlation with subsequent re-excision findings. BCS, DCIS
16  2019 Diagnostic Performance of Diffusion Tensor Imaging for Characterizing Breast Tumors: A Comprehensive Meta-Analysis. AUC, DCIS, DTI, FA, MD
17  2019 Differentiation between idiopathic granulomatous mastitis and invasive breast carcinoma, both presenting with non-mass enhancement without rim-enhanced masses: The value of whole-lesion histogram and texture analysis using apparent diffusion coefficient. IGM
18  2019 Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. COX-2, DCIS
19  2019 Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Detection in Invasive Breast Carcinoma: A Retrospective Study of 12,467 Patients From 19 Chinese Representative Clinical Centers. ER, HER2, HR, IHC, PR
20  2019 Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score! DCIS
21  2019 Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance. NAC, PI, QA
22  2019 Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution? CTCs
23  2019 Promoter hypermethylation in ductal carcinoma in situ of the male breast. BC, DCIS
24  2019 The clinicopathological significance of ubiquitin-conjugating enzyme E2C, leucine-rich repeated-containing G protein-coupled receptor, WW domain-containing oxidoreductase, and vasculogenic mimicry in invasive breast carcinoma. DFS, LNM, MVD, OS, TNM, UBE2C, VM, WWOX
25  2019 The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma insitu. CTSA, DCIS, DCIS/IBC, RFI
26  2018 ER-/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis. DFS, ER, OS, PR
27  2018 High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer. DFS, ER, HER2, OS, PR, RBM3
28  2018 Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. DCIS, FFPE, pDCIS
29  2017 Correlation between obesity and prognostic/predictive parameters with emphasis on the importance of lymph node metastases in patients with invasive breast carcinoma. ECE, LNR, NW, OB, OW
30  2017 Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma. DCIS, ECM
31  2017 Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma. DFS
32  2017 Proline-Rich Homeodomain protein (PRH/HHEX) is a suppressor of breast tumour growth. DCIS
33  2016 Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. BCS, DCIS
34  2016 Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. DCIS, HER2-AAbs, HR, OR
35  2015 Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer. CNA, DCIS
36  2015 Diffusion-tensor imaging as an adjunct to dynamic contrast-enhanced MRI for improved accuracy of differential diagnosis between breast ductal carcinoma in situ and invasive breast carcinoma. ADC, Davg, DCE-MRI, DCIS, DTI, EA, FA, RA, ROC, TIC, VR
37  2015 Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer. DFS, EMT, OS
38  2015 Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology. CISH, DCIS, lncRNAs, NA
39  2014 Complexity in regulation of microRNA machinery components in invasive breast carcinoma. Ago2, DGCR8, miRNA
40  2014 Reduced MUC4 expression is a late event in breast carcinogenesis and is correlated with increased infiltration of immune cells as well as promoter hypermethylation in invasive breast carcinoma. ---
41  2014 Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. ---
42  2013 Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. DCIS, EGFR, ER, HER2, PR
43  2013 False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. DDISH, IHC, TMA
44  2013 Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. DFS, NE, OS
45  2013 Patients with nipple-areola Paget's disease and underlying invasive breast carcinoma have very poor survival: a matched cohort study. HER2, OS, PD, RFS
46  2012 Genetic alterations in benign, preneoplastic and malignant breast lesions. BBL, BC, IDPL, MN
47  2012 Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. ER, FFPE, FNAC, HER2, HR, PR, TP
48  2012 Significance of stromal decorin expression during the progression of breast cancer. DCIS, ECM
49  2011 Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients. DCIS
50  2011 Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study. COX-2, DCIS
51  2010 p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions. ---
52  2008 Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer. DM, IBF
53  2008 Scoring index for prediction of HER-2 status in the invasive breast carcinoma. ER, HERSI, HG, PR
54  2007 Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material. IS-RT-PCR, LNM, MMPs, PDIBC
55  2006 Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. PD, RS
56  2005 A putative role for psoriasin in breast tumor progression. DCIS, ROS, VEGF
57  2005 Identification of BCOX1, a novel gene overexpressed in breast cancer. DCIS, MET
58  2005 The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. DCIS
59  2004 Low prebiopsy state irritability scores at the clinical onset of invasive breast carcinoma. PSE
60  2002 Low psychopathology scores in the prognosis of breast cancer. A preliminary report. PSE
61  2002 Predictive model of axillary lymph node involvement in women with small invasive breast carcinoma: axillary metastases in breast carcinoma. AD, ALNI
62  1999 Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. ER
63  1998 Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. OS
64  1997 Low and high molecular weight cytokeratins in invasive breast carcinoma. ER, HCK, LCK, OS, RFS
65  1990 Fibronectin: a discrimination marker between small invasive carcinomas and benign proliferative lesions of the breast. FN
66  1988 Stromal fibronectin staining pattern and metastasizing ability of human breast carcinoma. FN
67  1984 Precancerous and cancerous breast lesions during lifetime and at autopsy. A study of 83 women. ---